olaparib
astrazeneca,merck
['1357o', 'crpc', 'prostate', 'propel', 'brca', 'olaparib']
#esmo22 abs# 1357o: updated results from the phase iii propel trial showed rpfs benefit of using aap + olaparib in non-hrrm, hrrm, &amp; brcam status; hr 0.76, 0.50, and 0.23, respectively in mcrpc #prostatecancer. 
DM Clinical Hematology/BMT (PGI, Chandigarh), Hematology/Oncology Fellow at Huntsman Cancer Institute, SLC, Utah, United States ( GU Oncologist in making !!??)